NGS0.1%

NGS 0.1% ophthalmic suspension is a corticosteroid eye drop indicated for the treatment of steroid-responsive inflammatory conditions of the eye. Its use is supported by regulatory approval as follows:

FDA-Approved Indication

• NGS 0.1% is indicated for the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, iritis, cyclitis, and selected infective conjunctivitides where the inherent hazard of steroid use is accepted to obtain an advantage in diminishing edema and inflammation.

Common Clinical Uses (Guideline-Supported / Adjunct)

• Post-operative ocular inflammation following cataract or refractive eye surgery, usually as an adjunct in the peri-operative regimen.
• Anterior uveitis and iritis, often as part of a broader treatment plan alongside cycloplegics or other agents.
• Vernal keratoconjunctivitis and other allergic ocular surface conditions unresponsive to antihistamines or mast-cell stabilizers.

Note: NGS 0.1% should be used only under ophthalmologist supervision, as inappropriate use in viral, fungal, or mycobacterial eye infections can worsen the underlying condition (see Contraindications).

Each mL of NGS 0.1% ophthalmic suspension typically contains 1 mg (0.1% w/v) of NGS 0.1% as the active ingredient, with benzalkonium chloride as preservative and excipients including sodium chloride, edetate disodium, hydroxyethyl cellulose, tyloxapol, and purified water, with pH adjusted using hydrochloric acid and/or sodium hydroxide.

NGS 0.1% is a synthetic corticosteroid formulated as a sterile ophthalmic suspension for topical use in the eye. It belongs to a family of ocular anti-inflammatory agents used to control inflammation and reduce swelling, redness, and discomfort associated with various eye conditions. NGS 0.1% is available as an eye drop suspension intended for short- to medium-term use under medical supervision, for ophthalmic (topical eye) use only.

NGS 0.1% belongs to the therapeutic class of ophthalmic corticosteroids (topical anti-inflammatory agents), used specifically for controlling ocular surface and anterior segment inflammation.

NGS 0.1% is a corticosteroid that suppresses the inflammatory response to a variety of inciting agents including mechanical, chemical, and immunological triggers. It works by inhibiting release of inflammatory mediators (prostaglandins and other arachidonic acid metabolites) and reducing capillary permeability, edema, fibrin deposition, and leukocyte infiltration at the site of inflammation, thereby diminishing the clinical signs of inflammation.

Compared to some other topical ophthalmic corticosteroids (e.g. dexamethasone), NGS 0.1% has been noted in clinical studies to have a longer average time to produce a measurable rise in intraocular pressure (IOP), sometimes cited as a relatively favorable IOP profile among ophthalmic steroids. However, this does not mean NGS 0.1% is free of IOP-elevation risk, and the eventual magnitude of pressure rise with prolonged use can be comparable to other steroids; regular monitoring is still required (see Precautions and Warnings).

To administer NGS 0.1%: wash hands thoroughly, shake the bottle well, tilt the head back, gently pull down the lower eyelid to form a small pocket, and instill the prescribed number of drops without letting the dropper tip touch the eye, eyelid, or any surface. Close the eye gently for 1-2 minutes and apply light pressure at the inner corner of the eye (punctal occlusion) to reduce systemic absorption. Remove contact lenses before instilling NGS 0.1% and wait at least 15 minutes before reinserting them, as the preservative benzalkonium chloride may be absorbed by soft contact lenses. If using other eye drops concurrently, space administration at least 5 minutes apart.

Formal drug-drug interaction studies with NGS 0.1% are limited given its topical ophthalmic use and low systemic absorption. Clinically relevant considerations include:

• Other topical ophthalmic corticosteroids or NSAIDs: concurrent use with NGS 0.1% may increase the risk of corneal thinning, delayed wound healing, or additive intraocular pressure elevation; combination should be supervised by an ophthalmologist.
• Other topical eye medications: when multiple eye drops are prescribed together with NGS 0.1%, they should be administered at least 5 minutes apart to prevent dilution or washout of either product.
• Soft contact lenses: the preservative in NGS 0.1% (benzalkonium chloride) can be absorbed by soft contact lenses; lenses should be removed prior to instillation.

Adverse effects associated with NGS 0.1% are generally local to the eye and depend on dose and duration of use.

Common

• Transient burning, stinging, or discomfort on instillation
• Blurred vision immediately after application
• Eye irritation or foreign body sensation

Less Common / Serious (usually with prolonged use)

• Elevated intraocular pressure / glaucoma with possible optic nerve damage and visual field defects
• Posterior subcapsular cataract formation
• Secondary ocular infection (bacterial, viral, or fungal) due to masking or suppression of the immune response
• Delayed corneal or scleral wound healing; rarely, corneal/scleral perforation in eyes with pre-existing thinning
• Altered taste (dysgeusia) reported post-marketing
• Rarely, systemic effects such as adrenal suppression or Cushing's syndrome features with excessive/prolonged use

Pregnancy: There are no adequate and well-controlled studies of NGS 0.1% in pregnant women. Animal reproduction studies with fluorometholone have shown embryocidal and teratogenic effects (including fetal loss and abnormalities such as cleft palate, rib cage deformities, limb anomalies, and neural defects) at low multiples of the human topical dose. NGS 0.1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only under the direct advice and supervision of a physician.

Lactation: It is not known whether topical ophthalmic NGS 0.1% is excreted in human breast milk; however, systemically administered corticosteroids do appear in breast milk. Caution should be exercised, and a physician should be consulted, when NGS 0.1% is prescribed to a nursing mother.

The following precautions apply to the use of NGS 0.1%:

• Intraocular pressure (IOP): Prolonged use of NGS 0.1% (beyond 10 days) may cause elevated IOP, glaucoma, optic nerve damage, and visual field/acuity defects. IOP should be monitored periodically, especially with extended use.
• Cataracts: Prolonged use may lead to posterior subcapsular cataract formation.
• Infection risk: NGS 0.1% may suppress the immune response and mask signs of infection, or worsen existing viral, fungal, or bacterial ocular infections; it should not be used for undiagnosed red eye. If a fungal infection is suspected, the product should be discontinued immediately.
• Delayed wound healing: Corticosteroids like NGS 0.1% may slow corneal/scleral wound healing and, in diseases causing thinning of the cornea or sclera, may increase the risk of perforation.
• Duration of use: Use for the shortest duration necessary; avoid abrupt discontinuation after prolonged therapy without physician guidance. Only one bottle should be prescribed initially, with re-evaluation before any refill.
• Contact lenses: Remove soft contact lenses before instilling NGS 0.1%, as the preservative may be absorbed by the lens material.
• For ophthalmic use only: Not for injection or oral use.

Topical ocular overdose of NGS 0.1% (e.g. excessive or overly frequent instillation) may cause increased local irritation or worsening of steroid-related ocular side effects such as elevated intraocular pressure. If NGS 0.1% is accidentally ingested, seek immediate medical attention or contact a poison control center; excess product in the eye can be flushed with lukewarm water. Do not attempt to manage a suspected overdose at home without professional guidance.

Store NGS 0.1% ophthalmic suspension upright, between 2°C and 25°C (36°F to 77°F); protect from freezing and excessive heat. Keep the bottle tightly closed and protected from light. Keep out of reach of children. Discard any unused portion after the labeled in-use period following opening.

Pediatric Use: The safety and effectiveness of NGS 0.1% in pediatric patients have not been established. If used in children, they may be at increased risk of systemic corticosteroid effects such as adrenal suppression or Cushing's syndrome compared to adults; use only under close pediatric ophthalmology supervision.

Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger adult patients using NGS 0.1%; no dose adjustment is generally required based on age alone.

Renal/Hepatic Impairment: No specific dose adjustment of NGS 0.1% is established or generally required for renal or hepatic impairment, given minimal systemic absorption with topical ophthalmic use; caution is advised in patients with significant hepatic disease if prolonged or high-dose use occurs.

The duration of treatment with NGS 0.1% depends on the severity and response of the underlying inflammatory eye condition, and should be determined by the prescribing ophthalmologist. Treatment is generally intended to be short-term (days to a few weeks); use beyond 10 days requires periodic monitoring of intraocular pressure. Only one bottle of NGS 0.1% should be dispensed initially, and continued or refill use should follow re-assessment by the physician. Therapy should not be stopped or extended without medical advice.

NGS 0.1% belongs to the drug class of synthetic corticosteroids, specifically the subclass of topical ophthalmic corticosteroids / ocular anti-inflammatory agents.

NGS 0.1% acts by binding to glucocorticoid receptors within ocular tissue, inhibiting phospholipase A2 and thereby reducing synthesis of prostaglandins and other inflammatory mediators. This suppresses vascular permeability, leukocyte migration, and fibrin/collagen deposition at the site of inflammation, leading to a reduction in redness, swelling, and discomfort associated with steroid-responsive ocular inflammatory conditions.

C

The safety and effectiveness of NGS 0.1% in pediatric patients have not been formally established in controlled trials. When NGS 0.1% is prescribed for a child by an ophthalmologist, close monitoring is recommended given the theoretical increased risk of systemic corticosteroid absorption and effects (e.g. adrenal suppression) in children compared with adults. Use in children should be limited to the lowest effective dose for the shortest necessary duration, under specialist supervision.